retatrutide receptors Diagram showing the mechanism of action of Retatrutide | GLP-1R/GIPR/GCGR ligand |

Researchers continue to monitor long-term safety outcomes as additional Phase 3 studies progress

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a median 34.2 months in patients with overweight or obesity and pre-existing cardiovascular disease, independent of glycemic status [12]

this confirms that the initial rhythm was orthodromic AVRT Tall R waves in right precordial leads (V1-3) indicate a left-sided AP Antidromic AVRT Antidromic AVRT is rare, and makes up only 5% of tachyarrhythmias in patients with WPW

Direct head-to-head trials between retatrutide and semaglutide have not yet been completed, making definitive comparisons challenging

Week one is just the body clearing out

N Engl J Med 2021;384:1113-24.ArticlePubMed 110